Has the survival of the graft improved after renal transplantation in the era of modern immunosuppression?

Nefrologia

Volumn 33, Issue 1, 2013, Pages 14-26

  Moreso, Francesc ^a   Hernández, Domingo ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Acute rejection; Chronic rejection; Graft survival; Immunosupression; Renal transplantation

Indexed keywords

GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MORTALITY; RISK FACTOR; SHORT SURVEY; SURVIVAL RATE; TREATMENT FAILURE;

GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; RISK FACTORS; SURVIVAL RATE; TREATMENT FAILURE;

EID: 84873710315     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2012.Oct.11739     Document Type: Short Survey

References (96)

1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725-30.
2. Registro Español de Enfermos Renales. Informe 2006 de diálisis y trasplante renal en España. Nefrología 2009;29(6):525-33.
3. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:605-12.
4. Meier-Kriesche HU, Schold JD, Kaplan D. Long-term renal allograft survival: have we made significant progress or it is time to rethink our analytic and therapeutic strategies? Am J Transplant 2004;4:1289-95.
5. Registre de malalts renals de Catalunya. Informe estadístic 2010. Barcelona: Servei Català de la Salut. Organització Catalana de Trasplantaments (OCATT); mayo 2012.
6. Serón D, Arias M, Campistol JM, Morales JM. Late renal allograft failure between 1990 and 1998 in Spain: a changing scenario. Transplantation 2003;76:1588-93.
7. Solez K, Axelsen RA, Beneditksson H, Burdick JF, Cohen AH, Colvin RB, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993;44:411-22.
8. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff working classification of renal allograft pathology. Kidney Int 1999;55:713-23.
9. Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004;4(10):1562-6.
10. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, et al. Banff '05 Meeting Report:differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007;7(3):518-26.
11. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008;8:753-60.
12. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349(24):2326-33.
13. Chapman J, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005;16:3015-26.
14. Ferrari-Lacraz S, Tiercy JM, Villard J. Detection of anti-HLA antibodies by solid-phase assay in kidney transplantation: friend or foe? Tissue Antigens 2012;79:315-25.
15. Serón D, Moreso F, Arias M, Campistol JM, Curto J, Hernandez D, et al. Estimation of renal allograft half life:fact or fiction? Nephrol Dial Transplant 2011;26(9):3013-8. Erratum in: Nephrol Dial Transplant 2011;26(12):4153-4.
16. Hernández D, Sánchez Fructuoso A, Serón D, Arias M, Campistol JM, Morales JM, et al. Chronic transplant nephropathy. Nefrologia 2006;26 Suppl 1:1-38.
17. El-Zoghby ZM, Stegall MD, Lager DJ, Kremers WK, Amer H, Gloor JM, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009;9:527-35.
18. ANZDATA Registry Report 2004. Edited by McDonald S, Excell L. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia.
19. Hoogland ER, Snoeijs MG, Winkens B, Christaans MH, van Heurn LW. Kidney transplantation from donors after cardiac death: uncontrolled versus controlled donation. Am J Transplant 2011;11:1427-34.
20. Chang SH, Russ GR, Chadban SJ, Campbell SB, McDonald SP. Trends in kidney transplantation in Australia and New Zealand, 1993-2004. Transplantation 2007;84:611-8.
21. Collaborative Transplant Study. CTS Outcome Graphs. 2011; Graph K-14103E-0711. Available at: http://www.ctstransplant.org/public/introduction.shtml.
22. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011;11:450.
23. Sola E, Gonzalez-Molina M, Cabello M, Burgos D, Ramos J, Gutierrez C, et al. Long-term improvement of deceased donor renal allograft survival since 1996: a single transplant center study. Transplantation 2010;89(6):714-20.
24. Moreso F, Alonso A, Gentil MA, González-Molina M, Capdevila L, Marcén R, et al. Improvement in late renal allograft survival between 1990 and 2002 in Spain: results from a multicentre casecontrol study. Transpl Int 2010;23(9):907-13.
25. Ojo AO, Morales JM, González-Molina M, Steffick DE, Luan FL, Merion RM, et al. Comparison of the long-term outcomes of kidney transplantation: USA versus Spain. Nephrol Dial Transplant 2012. doi:10.1093/ndt/gfs287 [Epub ahead of print].
26. Seron D, Moreso F. Protocol biopsies in renal transplantation: Prognostic value of structural monitoring. Kidney Int 2007;72:690-7.
27. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005;5:2464-72.
28. Moreso F, Ibernon M, Gomà M, Carrera M, Fulladosa X, Hueso M, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006;6(4):747-52.
29. Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, et al. Evidence for antibody-mediated rejection injury as a major determinant of late kidney allograft failure. Transplantation 2010;90:68-74.
30. Sellares J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the causes of kidney transplant failure:the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012;12:388-99.
31. Nankivell BJ, Borrows RJ, Fung CLS, O'Connell PJ, Allen RDM, Chapman JR. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004;78:242.
32. Loupy A, Souberbille-Boissel C, Hill GS, Lefaucheur C, Anglicheau D, Zuber J, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donorspecific antibodies. Am J Transplant 2009;9:2561-70.
33. Hill GS, Nochy D, Bruneval P, Duong van Huyen JP, Glotz D, Suberbielle C, et al. Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol 2011;22:975-83.
34. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity:longitudinal assessment by protocol histology. Transplantation 2004;78:557-65.
35. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009;4:481-508.
36. Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin J Am Soc Nephrol 2009;4:2029-34.
37. Krejci K, Tichy T, Hruby M, Horak P, Ciferska H, Horcicka V, et al. Subclinical toxicity of calcineurin inhibitors in repeated protocol biopsies: an independent risk factor for chronic kidney allograft damage. Transpl Int 2010;23(4):364-73.
38. Arias M, Seron D, Moreso F, Bestrard O, Praga M. Chronic renal allograft damage: Existing challenges. Transplantation 2011;91(9 Suppl):S4-S25.
39. Cosio FG, Qiu W, Henry ML, Falkenhain ME, Elkhammas EA, Davies EA, et al. Factors related to the donor organ are major determinants of renal allograft function and survival. Transplantation 1996;62(11):1571-76.
40. Anglicheau D, Loupy A, Lefaucheur C, Pessione F, Létourneau I, Côté I, et al. A simple clinico-histopathological composite scoring system is highly predictive of graft outcomes in marginal donors. Am J Transplant 2008;8(11):2325-34.
41. Brenner BD, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982;309:652-9.
42. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy:the concept of accelerated senescence. J Am Soc Nephrol 1999;10:167-81.
43. Nankivell BJ, Kuypers DRJ. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011;378:1428-37.
44. Ekberg H, Johansson ME. Challenges and considerations in diagnosing the kidney disease in deteriorating graft function. Transpl Int 2012;25(11):1119-28.
45. Opelz G, Döhler B. Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation 2007;84:137-43.
46. Pascual J, Royuela A, Galeano C, Crespo M, Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transplant 2012;27:825-32.
47. Clayton P, McDonald S, Chadban S. Steroids and recurrent IgA nephropathy after kidney transplantation. Am J Transplant 2011;11:1645-49.
48. McDonald S, Russ G, Campbell S, Chadban S. Kidney transplant rejection in Australia and New Zealand: relationships between rejection and graft outcome. Am J Transplant 2007;7:1201-8.
49. Moreso F, Seron D, Carrera M, Gil-Vernet S, Cruzado JM, Hueso M, et al. Baseline immnosuppression is associated with histological findings in early protocol biopsies. Transplantation 2004;78(7):1064-8.
50. Rush D, Arlen D, Boucher A, Busque S, Cockfield SM, Girardin C, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant 2007;7:2538-45.
51. Hernández D, Pérez G, MarreroD, Porrini E, Rufino M, González-Posada JM, et al. Early association of low-grade albuminuria and allograft dysfunction predicts renal transplant outcomes. Transplantation 2012;93:297-303.
52. Moreso F, Seron D, Gil-Vernet S, Riera L, Fulladosa X, Ramos R, et al. Donor age and delayed graft function as predictors of renal allograft survival in rejection-free patients. Nephrol Dial Transplant 1999;14:930-5.
53. Radermacher J, Mengel M, Ellis S, Stuht S, Hiss M, Schwarz A, et al. The renal arterial resistance index and renal allograft survival. N Engl J Med 2003;349:115-24.
54. Vallejos A, Alperovich G, Moreso F, Cañas C, de Lama ME, Gomà M, et al. Resistive index and chronic allograft nephropathy evaluated in protocol biopsies as predictors of graft outcome. Nephrol Dial Transplant 2005;20:2511-6.
55. Donnelly PK, Simpson AR, Milner AD, Nicholson ML, Horsburgh T, Veitch PS, et al. Age-matching improves the results of renal transplantation with older donors. Nephrol Dial Transplant 1990;5:808-11.
56. Waiser J, Schreiber M, Budde K, Fritsche L, Bohler T, Hauser I, et al. Age-matching in renal transplantation. Nephrol Dial Transplant 2000;15:696-700.
57. Kasiske BL, Snyder J. Matching older kidneys with older patients does not improve allograft survival. J Am Soc Nephrol 2002;13:1067-72.
58. Sola R, Guirado L, Lopez-Navidad A, Bonfill X, Diaz JM, Puig T, et al. Is it appropriate to implant kidneys from elderly donors in young recipients? Transplantation 2010;90:286-91.
59. Textor S, Nyberg S. Recipient and donor age in deceased donor transplantation: how should older donor kidneys be allocated? Transplantation 2010;90:246-7.
60. Danovitch GM, Cohen B, Smits JM. Waiting time or wasted time? The case for using time on dialysis to determine the waiting time in the allocation of cadaveric donors. Am J Transplant 2002;2:891-3.
61. Baskin-Bey ES, Kremers W, Nyberg SL. A recipient risk score for deceased donor renal allocation. Am J Kidney Dis 2007;49:284-93.
62. Baskin-Bey ES, Nyberg SL. Matching graft to recipient by predicted survival: can this be an acceptable strategy to improve utilization of deceased donor kidneys? Transplant Rev (Orlando) 2008;22:167-70.
63. Terasaki PI. Cold ischemia time-time to rethink the risk for kidneys. Am J Transplant 2011;11:2551-2.
64. Dikdan GS, Mora-Esteves C, Koneru B. Review of randomized clinical trials of donor management and organ preservation in deceased donors: opportunities and issues. Transplantation 2012;94:425-41.
65. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, et al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-75.
66. Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005;(4):CD003961.
67. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997;63:39-47. Erratum in: Transplantation 1997;63:618.
68. Remuzzi G, Cravedi P, Costantini M, Lesti M, Ganeva M, Gherardi G, et al. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: The MYSS follow-up, randomized, controlled clinical trial. J Am Soc Nephrol 2007;18:1973-85.
69. Clayton PA, McDonald SP, Chapman JR, Chadban SJ. Mycophenolate versus azathioprine for kidney transplantation: a 15-year follow-up of a randomized trial. Transplantation 2012;94:152-8.
70. Moreso F, Algre R, Bernis C, Beneyto I, Crespo JF, Delgado P, et al. Riesgo cardiovascular e hipertensión arterial postrasplante renal. Nefrologia 2009;29(Suppl 3):11-5.
71. Cross NB, Webster AC, Masson P, O'Connell PJ, Craig JC. Antihypertensive treatment for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009;88:7-18.
72. Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, et al. Angiotensin-converting enzyme inhibitor or angiotensin II receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006;17:889-99.
73. Opelz G, Zeier M, Laux G, Morath C, Döhler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers:a collaborative transplant study report. J Am Soc Nephrol 2006;17:3257-62.
74. Hernández D, Muriel A, Abraira V, Pérez G, Porrini E, Marrero D, et al. Renin-angiotensin system blockade and kidney transplantation: a longitudinal cohort study. Nephrol Dial Transplant 2012;27:417-22.
75. Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA. Reninangiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007;7:2350-60.
76. Hernández AA, Moreso F, Bayés B, Lauzurica R, Sanz-Guajardo D, Gómez-Huertas E, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain. NDT Plus 2010;(Suppl 2):ii21- ii25.
77. Ibernon M, Moreso F, Sarrias X, Sarrias M, Grinyó JM, Fernandez-Real JM, et al. Reverse dipper pattern of blood pressure at 3 months is associated with inflammation and outcome after renal transplantation. Nephrol Dial Transplant 2012;27:2089-95.
78. Moreso F, Alegre R, Beneyto I, Bernis C, Calvo N, Crespo JF, et al. Consecuencias clínicas de la diabetes mellitus posterior al trasplante renal. Nefrologia Supl Ext 2010;1(2):15-20.
79. Bhalla V, Nast CC, Stollenwer N, Tran S, Barba L, Kamil ES, et al. Recurrent and de novo diabetic nephropathy in renal allografts. Transplantation 2003;75:66-71.
80. Seron D, Oppenheimer F, Pallardo LM, Lauzurica R, Errasti P, Gomez-Huertas E, et al. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double-blind, placebo-controlled study. Transplantation 2008;86:82-7.
81. Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361(9374):2024-31.
82. Moreso F, Calvo N, Pascual J, Anaya F, Jiménez C, Del Castillo D, et al. Early statin use is an independent predictor of long-term graft survival. NDT Plus 2010;(Suppl 2):ii26-ii31.
83. Moreso F, Alegre R, Ariceta G, Beneyto I, Bernis C, Calvo N, et al. Tratamiento de la anemia postrasplante renal. Nefrologia Supl Ext 2011;2(2):16-24.
84. Choukroun G, Kamar N, Dussol B, Etienne I, Cassuto-Viguier E, Toupance O, et al. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol 2012;23:360-8.
85. Srinivas TR, Flechner SM, Poggio ED, Askar M, Goldfarb DA, Navaneethan SD, et al. Glomerular filtration rate slopes have significantly improved among renal transplants in the United States. Transplantation 2010;90:1499-505.
86. Gill JS, Tonelli M, Mix CH, Pereira BJG. The change in allograft function among long-term kidney transplant recipients. J Am Soc Nephrol 2003;14:1636-42.
87. Khalkhali HR, Ghafari A. Prediction of long-term kidney failure in renal transplant with chronic dysfunction using stage-specific hazar rates. Exp Clin Transplant 2012;10:8-13.
88. Metzger RA, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion RM. Expanded criteria donors for kidney transplantation. Am J Transplant 2003;(3 suppl 4):114.
89. Nyberg SL, Matas AJ, Kremers WK, Thostenson JD, Larson TS, Prieto M, et al. Improved scoreing sytem to assess adult donors for cadaver renal transplantation. Am J Transplant 2003;3:715-21.
90. Schold JD, Kaplan B, Baliga RS, Meier-Kriesche HU. The broad spectrum of quality in deceased donors kidneys. Am J Transplant 2005;(4 pt 1):757-65.
91. Rao PS, Schaubel DE, Guidinger MK, Andreoni KA, Wolfe RA, Merion RM, et al. A comprehensive risk quantification score for deceased donor kidneys: The Kidney Donor Risk Index. Transplantation 2009;88:231-6.
92. Irish WD, McCollum DA, Tesi RJ, Owen AB, Brennan DC, Bailly JE, et al. Nomogram for prediciting the likelihood of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. J Am Soc Nephrol 2003;14:2967-74.
93. Moore J, Ramakrishna S, Tan K, Cockwell P, Eardley K, Little MA, et al. Identification of the optimal donor quality scoring system and measure of early renal function in kidney transplantation. Transplantation 2009;87:578-86.
94. Kaplan B, Schold J, Meier-Kriesche HU. Poor predictive value of serum creatinine for renal allograft loss. Am J Transplant 2003;3:1560-5.
95. Schold JD, Kaplan B. AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. Am J Transplant 2009;9:2067-74.
96. Schold JD, Kaplan B. The elephant in the room: failings of current clinical endpoints in kidney transplantation. Am J Transplant 2010;10:1163-6.